Drug Profile
DS 1442
Alternative Names: DS-1442Latest Information Update: 02 Oct 2014
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 31 Jul 2014 Discontinued - Phase-I for Dyslipidaemias (unspecified route)
- 31 Oct 2012 Phase-I clinical trials in Dyslipidaemias (unspecified route)